drugset
drugset / Trial / NCT03381547

A 3-Way Crossover Study to Evaluate the Pharmacokinetics in Participants After Dosing With Pegilodecakin (LY3500518)

NCT03381547 ↗

Phase 1 Completed 12 enrolled Eli Lilly and Company ARMO BioSciences · collab
RandomizedCrossoverOpen-labelBasic science

Summary

To evaluate the pharmacokinetics of different dose levels and dose formulations of pegilodecakin in healthy adult participants.

Timeline

Start
2017-12-18
Primary completion
2018-02-13
Completion
2018-02-13

Drugs

EvaluationDrugModalityDoseRoute
Subject Pegilodecakin Protein / enzyme biologic 0.4 mg Subcutaneous
Subject Pegilodecakin Protein / enzyme biologic 0.8 mg Subcutaneous
Subject Pegilodecakin Protein / enzyme biologic 1.6 mg Subcutaneous

Indications

No indication recorded.